摘要嵌合抗原受体T细胞(CAR-T)免疫疗法是近年来极具发展前景的免疫过继疗法之一。CAR-T免疫原性与抗嵌合抗原受体(CAR)特异性免疫反应可导致CAR-T体内扩增能力下降及存活时间缩短，从而导致原发疾病复发，限制其临床应用。CAR-T免疫原性的影响因素众多，其中研究最为广泛的是鼠源性单链可变区(scFv)构建CAR结构所产生的免疫原性。目前已有多种降低CAR-T免疫原性，从而延长CAR-T体内存活时间，增强疗效的方法，如解决CAR结构非人源化问题等。为了深入探讨影响CAR-T免疫疗法疗效及安全性的相关因素，笔者拟就CAR-T的免疫原性、其产生的免疫反应进行阐述，同时探讨可降低CAR-T免疫原性的相关措施，以期进一步增加CAR-T免疫疗法的临床应用。

abstractsChimeric antigen receptor T cell (CAR-T) immunotherapy is one of the most promising immunological adoptive therapies in recent years. Immunogenicity of CAR-T and anti-chimeric antigen receptor (CAR) specific immune response limit the expansion of CAR-T in vivo and shorten the persistence of CAR-T, which cause the recurrence of primary disease and limit its clinical application. There are many factors affecting immunogenicity of CAR-T, among which the most widely studied, is the murine single-chain variable region (scFv) of CAR structure. There are currently a variety of strategies to reduce the immunogenicity of CAR-T, thus extending the persistence of CAR-T in vivo and enhancing the efficacy therefore, such as solving the problem of non-humanized CAR structure. In order to investigate the factors affecting the efficacy and safety of CAR-T immunotherapy, this article intends to elaborate on the immunogenicity of CAR-T, immune response it generates, as well as to discuss measures that can reduce the immunogenicity of CAR-T, to further increase the clinical application of CAR-T immunotherapy.